Pharmacogenetics and cancer therapy

Nature Reviews Cancer

Volumn 1, Issue 2, 2001, Pages 99-108

  Relling, Mary V ^a   Dervieux, Thierry ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYTOCHROME P450; DRUG RECEPTOR; ENZYME INHIBITOR; FOLIC ACID ANTAGONIST; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; METHYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE; TRANSFERASE;

BIOTRANSFORMATION; CLASSIFICATION; FORECASTING; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; NEOPLASM; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; METHYLTRANSFERASES; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DRUG; TRANSFERASES; VARIATION (GENETICS);

EID: 0035524458     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/35101056     Document Type: Article

References (24)

1. Ratain, M. J. & Relling, M. V. Gazing into a crystal ball - cancer therapy in the post-genomic era. Nature Med. 7, 283-285 (2001).
2. Klausner, R. D. Cancer, genomics, and the National Cancer Institute. J. Clin. Invest. 104, 15-17 (1999).
3. Vogel, F. Moderne probleme der humangenetik. Ergebnisse Inneren Medizin und Keinderheilkunde 12, 52-125 (1959).
4. Evans, W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
5. Spannbrucker, N., Eichelbaum, M., Steinke, B. and Dengler, H. J. A human genetic defect in the metabolism of sparteine. Verh. Dtsch. Ges. Inn. Med. 84, 1125-1127 (1978).
6. Gonzalez, F. J. et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331, 442-446 (1988). The genetic basis underlying individual variations in responses to the antihypertensive drug debrisoquine. Poor drug metabolizers were found to express negligible amounts of the cytochrome P450 enzyme P450db1. The authors cloned the human P450db1 cDNA and purified the protein, discovering one of the most commonly occuring mutations. This was the start of modern pharmacogenetics.
7. Mortimer, O. et al. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin. Pharmacol. Ther. 47, 27-35 (1990).
8. Meyer, U. A. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. Pharmacol. Ther. 46, 297-308 (1990).
9. Meyer, U. A. & Zanger, U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
10. Johansson, I. et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA 90, 11825-11829 (1993).
11. Sachidanandam, R. et al. A map of human genome sequence variation containing 1.42 million single nucleotids polymorphisms. Nature 409, 928-933 (2001). The work of several large collaborative groups, whose goal was to characterize the frequency and distribution characteristics of single nucleotide polymorphisms across the entire human genome.
12. Pastinen, T. et al. A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays. Genome Res. 10, 1031-1042 (2000).
13. Hoogendoom, B. et al. Cheap, accurate and rapid allele frequency estimation of single nucleotide polymorphisms by primer extension and DHPLC in DNA pools. Hum. Genet. 107, 488-493 (2000).
14. Giordano, M., Mellai, M., Hoogendoorn, B. & Momigliano-Richiardi. P. Determination of SNP allele frequencies in pooled DNAs by primer extension genotyping and denaturing high-performance liquid chromatography. J. Biochem. Biophys. Methods 47, 101-110 (2001).
15. Mein, C. A. et al. Evaluation of single nucleotide polymorphism typing with invader on PCR amplicons and its automation. Genome Res. 10, 330-343 (2000).
16. Hessner, M. J., Budish, M. A. & Friedman, K. D. Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes. Clin. Chem. 46, 1051-1056 (2000).
17. Pfost, D. R., Boyce-Jacino, T. & Grant, D. M. A SNP shot: pharmacogenetics and the future of drug therapy. Trends Biotechnol. 18, 334-338 (2000).
18. Pui, C. H. & Evans, W. E. Acute lymphoblastic leukemia. N. Engl. J. Med. 339, 605-615 (1998).
19. Elion, G. B. The purine path to chemotherapy. Science 24, 4411-447 (1989).
20. Relling, M. V. et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyl-transferase gene locus. J. Natl Cancer Inst. 91, 2001-2008 (1999).
21. Leonard, L, Lilleyman, J. S., Van Loon, J. & Weinshilboum, R. M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336, 225-229 (1990).
22. Lennard, L, Gibson, B. E., Nicole, T. & Lilleyman, J. S. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch. Dis. Child 69, 577-579 (1993).
23. Dervieux, T. et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res. 61, 5810-5816 (2001).
24. Weinshilboum, R. M. & Sladek, S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651-662 (1980). This survey of 298 blood donors established a trimodal distribution for erythrocyte thiopurine methyltransferase activity, and classical family studies established that the three phenotypes were due to monogenic autosomal codominant inheritance. The authors suggested that the polymorphism could be used to predict response to thiopurine therapy, which was subsequently verified in many studies.